Table. 3 Subgroup analysis of virologic, biochemical, and serologic responses of patients with only ETV resistance different rescue therapy at Week 48
ETV + ADV | TDF | TDF + ETV | |
|---|---|---|---|
N | 18 | 22 | 17 |
HBV DNA < 100 IU/mL, n (%) | 5, 27.28% | 15, 68.18% | 11, 64.71% |
HBV DNA change from baseline (log10 IU/mL) | 4.09 | 4.07 | 5.03 |
Residual HBV DNA level (log10 IU/mL) | 2.45 | 1.19 | 1.03 |
Virologic breakthrough | 0 | 0 | 0 |
ALT (IU/L) | 41.44 | 44.1 | 35.13 |
ALT normal, n (%) | 13, 72.22% | 19, 86.36% | 14, 82.35% |
Abnormal renal function | 0 | 0 | 1 |
HBeAg seroclearance, n (%) | 0 | 3, 13.64% | 1, 5.88% |
HBeAg seroconversion, n (%) | 0 | 1, 4.55% | 1, 5.88% |
HBsAg seroclearance, n (%) | 0 | 0 | 0 |
Discontinued | 3 | 1 | 0 |
12 weeks HBV DNA level (log10 IU/mL) | 3.75 | 2.47 | 2.83 |
24 weeks HBV DNA level (log10 IU/mL) | 2.44 | 1.36 | 1.84 |
48 weeks HBV DNA level (log10 IU/mL) | 2.45 | 1.19 | 1.03 |
12 weeks HBV DNA < 100 IU/mL, n (%) | 0.00% | 27.27% | 17.65% |
24 weeks HBV DNA < 100 IU/mL, n (%) | 16.67% | 54.55% | 41.18% |
48 weeks HBV DNA < 100 IU/mL, n (%) | 27.78% | 68.18% | 64.71% |